Our Expert Network

1. Tune Therapeutics' 2025 Epigenome Editing Outlook 1/10/2025

   Chief Scientific Officer Derek Jantz talks about recent key innovations in gene therapy and RNA technology while considering what milestones we might see in 2025.

2. RNA Therapeutics As We Enter 2025: Looking Beyond The Horizon Of First-Generation Success 1/9/2025

   As we enter 2025, RNA therapeutics are poised to command significant attention from industry leaders as well as emerging players.

3. 2025 Forecast For Advanced Therapies 1/8/2025

   As we reflect on the lessons from 2024, it’s time to consider what 2025 may hold for the industry. Special attention is given to oligos, mRNA, cell therapies, and AAV.

4. Go From Batch To Continuous RNA Purification With mAb Equipment And QBD 12/30/2024

   University of Sheffield researchers developed a novel method purify polyadenylated mRNA continuously, which stands to improve productivity and efficiency.

5. FDA Issues New Guidance: Nonclinical Safety Assessment Of Oligonucleotide-Based Therapeutics 12/11/2024

   FDA's CDER recently issued a draft guidance: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. This article provides a summary and analysis. The public comment period ends January 14, 2025.

6. Is Your CDMO Using These AI-Driven Solutions In CMC For Oligos And Peptides? 12/10/2024

   Oligonucleotides and peptides require precise, scalable, and compliant production. CDMOs are integrating AI-driven technologies to answer the call. Many of these technologies are notable for specific needs.

7. RNase Control: An Overview With Market Trends 12/2/2024

   This article shares an overview of ribonuclease (RNase) control and some associated macro market research.

8. Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 11/26/2024

   EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.

9. Sourcing Plasmid DNA From CDMOs Got More Challenging — Here's Why 11/19/2024

   The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.

10. CMC Strategies With CDMOs: Ensuring CQAs For Oligos And Peptides 11/18/2024

    Developing a practical chemistry, manufacturing, and controls (CMC) strategy for oligonucleotides and peptides demands a shift in approach in terms of the way you collaborate with your CDMO.